GlassScriptPhysician profile
Matthew S Kniss
NPI 1710936018
$5,094.21
in general payments reported to CMS, 2019-2025
60 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $395 · 2021: $932 · 2022: $797 · 2023: $933 · 2024: $739 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535 · Education: $56.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.56 |
| Education | $56.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.49 | 2021-2025 | |
| Ucb, INC. | $514.16 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Supernus Pharmaceuticals, INC. | $430.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $301.82 | 2019-2025 | |
| Biogen, INC. | $217.87 | 2019-2025 | Spinraza, Qalsody, Vumerity |
| Genentech USA, INC. | $184.63 | 2021-2023 | Ocrevus |
| Sk Life Science, INC. | $165.13 | 2022-2025 | |
| Neurelis, INC. | $158.18 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $138.00 | 2020-2023 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $128.05 | 2019-2025 | Ultomiris |
| Celgene Corporation | $118.24 | 2021-2024 | Zeposia |
| Genzyme Corporation | $106.57 | 2019-2025 | |
| Lundbeck LLC | $105.77 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $98.76 | 2024-2025 | Ponvory |
| Pfizer INC. | $98.52 | 2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kniss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.